除了流感，RSV病毒同样值得关注！解析RSV的F与G蛋白入侵细胞的机制

Core Insights - Respiratory Syncytial Virus (RSV) is a significant respiratory virus that poses health risks, particularly to children, the elderly, and immunocompromised individuals. In the U.S., nearly all children are infected by age two, leading to approximately 58,000 hospitalizations annually for children under five. Globally, RSV affects 64 million people and results in 160,000 deaths each year [2] Group 1: RSV Overview - RSV is an RNA virus that spreads through the air and is classified under the Pneumoviridae family. It has a genome consisting of 10 genes encoding 11 proteins, which can be categorized into target and non-target proteins [4] - The F protein is crucial for the fusion of the virus with host cells, while the G protein aids in viral attachment to host cell receptors. Both proteins are highly glycosylated and are considered primary targets for vaccine development due to their genetic and antigenic conservation [6][7] Group 2: Vaccine Development - The RSV vaccine market has seen significant advancements, with three new vaccines approved globally in 2023, all targeting the pre-F glycoprotein. GSK's Arexvy and Pfizer's Abrysvo have been launched, with Moderna's mRESVIA expected to be approved in 2024 [9] - Several companies, including domestic firms like Adimab and Clover Biopharmaceuticals, are actively developing RSV vaccines. Clover's SCB-1019, a bivalent recombinant pre-F candidate vaccine, has shown comparable neutralizing antibody levels to Arexvy in older adults during Phase I trials [9] Group 3: Ongoing Research and Clinical Trials - Ongoing RSV projects are primarily focused on vaccine development, with various candidates in different clinical trial phases. For instance, SP-0125 is in Phase III for infants, while several others are in Phase II and I for older adults [10] - The RSV research landscape includes a range of vaccine types, such as live attenuated, recombinant protein, and mRNA vaccines, indicating a diverse approach to combating RSV [9][10] Group 4: Antibody Development and Research Solutions - Yiqiao Shenzhou has developed stable trimeric constructs of RSV pre-F and post-F proteins, which are essential for antibody screening and vaccine development. Their product library includes various RSV targets and antibodies, supporting multiple research applications [13]